HONG KONG – Japan's Ministry of Health, Labour and Welfare gave the nod to Blincyto (blinatumomab) for use in relapsed or refractory B-cell acute lymphoblastic leukemia (ALL), marking the bispecific T-cell engager's entry into the Asian market, following approvals in the U.S., all members of the EU and European Economic Area, Canada and Australia.